Global Overactive Bladder Treatment Market Size, Share, Forecast Report, 2020-2027

The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.

Overactive Bladder (OAB) is a symptom syndrome characterized by urinary urgency. Numerous factors such as the growing prevalence of Overactive Bladder (OAB) coupled with the rising geriatric population, increasing occurrences of Parkinson’s disease, and multiple sclerosis and stroke are likely to drive the growth of the market during the forecast period. For instance, according to the data stated by the Official Foundation of the American Urological Association, in 2016, approximately 33 million Americans had an overactive bladder. It also mentioned that around 30% of men and 40% of women in the US have the symptoms of overactive bladder. Moreover, the development of innovative intravesical therapies and increasing marketing activities by pharma companies contribute to the growth of the market.

Company Profiles    

• Astellas Pharma Inc.
• Pfizer, Inc.
• Teva Pharmaceutical
• Allergan, Plc. 
• Mylan N.V. 
• Endo International Plc 
• Hisamitsu Pharmaceutical Co., Inc.
• Sanofi S. A.
• Aurobindo Pharma Limited 
• Johnson & Johnson
• Intas Pharmaceuticals Ltd. 
• Apotex Inc. 
• Macleods Pharmaceuticals Ltd. 
• Medtronic PLC
• Cogentix Medical, Inc.
• Others

Segmentation

The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.

On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.

The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.

On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.

Global Overactive Bladder Treatment Market, by Pharmacotherapy

• Anticholinergics
• Solifenacin
• Oxybutynin
• Fesoterodine
• Darifenacin
• Tolterodine
• Trospium
• Others
• Botox
• Mirabegron
• Neurostimulation
• Others

Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment

• Dietary and Fluid Modifications
• Behavioral Therapy
• Pelvic Floor Muscle Rehabilitation
• Others

Global Overactive Bladder Treatment Market, by Disease

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder
• Overactive Bladder in Parkinson’s Disease
• Overactive Bladder in Stroke
• Overactive Bladder in Multiple Sclerosis
• Overactive Bladder in Spinal Cord Injury
• Overactive Bladder in Other Disorders